This could explain why, in clinical trials of cancer treatment, oral administration of FK866 or CHS828,20, 21 which inhibits NAMPT enzymatic activity, caused unwanted side effects dominated by gastrointestinal symptoms. Here, NAMPT is linked to cancer.